USA flag logo/image

An Official Website of the United States Government

CANCER CHEMOTHERAPY IS WIDELY USED AND NEW AND MORE POTENT ANTINEOPLASTIC DRUGS…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
3106
Program Year/Program:
1985 / SBIR
Agency Tracking Number:
3106
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
THERATECH, INC.
417 Wakara Way Salt Lake City, UT 84108
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1985
Title: CANCER CHEMOTHERAPY IS WIDELY USED AND NEW AND MORE POTENT ANTINEOPLASTIC DRUGS ARE BEING CONTINUALLY DEVELOPED.
Agency: HHS
Contract: N/A
Award Amount: $45,850.00
 

Abstract:

CANCER CHEMOTHERAPY IS WIDELY USED AND NEW AND MORE POTENT ANTINEOPLASTIC DRUGS ARE BEING CONTINUALLY DEVELOPED. IN PRECLINICAL TOXICOLOGICAL STUDIES AND IN CLINICAL TRIALS OF SUCH NEW DRUGS, THE NATIONAL CANCER INSTITUTE UTILIZES INTRAVENOUS ROUTE AS THE PRIMARY MODE OF DRUG ADMINISTRATION. MOST OF THE DRUGS HAVE ADEQUATE INHERENT AQUEOUS SOLUBILITY AND STABILITY FOR INTRAVENOUS DELIVERY; FOR DRUGS HAVING LOW SOLUBILITY, EXISTING SOLUBILIZATION TECHNIQUES ARE USED TO INCREASE THE SOLUBILITY. HOWEVER, THERE ARE SEVERAL DRUGS THAT ARE CLINICALLY VERY PROMISING BUT ARE UNAVAILABLE TO CLINICIANS BECAUSE THEY CANNOT BE PROPERLY FORMULATED. THE GOAL OF PHASE I OF THIS PROGRAM IS TO DEMONSTRATE THE UTILITY OF A NOVEL PRODRUG DESIGN APPROACH TO SOLVING THE SOLUBILITY/STABILITY PROBLEMS ASSOCIATED WITH SUCH PROBLEMATIC DRUGS. WE WILL DEVELOP STABLE AQUEOUS FORMULATIONS USING NOVEL MICELLAR PRODRUGS OF N-TRIFLUOROACETYL ADRIAMYCIN. THE RESULTS OF PHASE I STUDIES WILL BE UTILIZED FOR THE PHASE II STUDIES IN WHICH WE WILL OPTIMIZE THE STRUCTURE OF THE PROMOIETY INCORPORATING INTO THE PRODRUG(S) THOSE STRUCTURAL FEATURES NECESSARY FOR ADEQUATE IN VIVO LABILITY AND SAFETY LEADING TO THE DEVELOPMENT OF COMMERCIALLY VIABLE PRODUCT(S). WE WILL FURTHER EXPLORE THE UTILITY OF OUR PRODRUG DESIGN APPROACH TO SOLVE THE SOLUBILITY/STABILITY PROBLEMS OF ONE OR TWO OTHER ANTICANCER DRUGS OF

Principal Investigator:

Dinesh c. patel
PRINCIPAL INVESTIGATOR
8015832608

Business Contact:

Small Business Information at Submission:

Therapeutics Technologies, Inc
417 Wakara Way,room 290 Salt Lake City, UT 84108

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No